FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2522016529> ?p ?o ?g. }

• W2522016529 abstract "Abstract Abstract 565FN2 Hyperdiploidy >50 chromosomes (HD>50) has long been recognized as favorable group in childhood B-ALL but there is still debate on the factors contributing to heterogeneity of prognosis observed within this entity. Better outcome has been reported for patients (pts) presenting DNA index (DI) >1.16 (Blood 1985;10:213), ≥56 chromosomes (Leukemia 1996;10:213), triple trisomies (TT) +4,+10,+17, double trisomies +4,+10 (Leukemia 2005;19:734) and trisomy 18 (Blood 2003;102:2756) but there is no consensus between the reports and these factors are differently applied in current protocols. We studied these factors in the pts with HD>50 enrolled in the ALL 58951 trial, BFM related. HD>50 were detected by cytogenetics (karyotype/FISH) and/or flow cytometry (DI). In order to analyze the outcome of HD>50 itself, pts with recurrent unfavorable translocations t(9;22), 11q23/MLL+, with t(1;19), t(12;21) or Down Syndrome were excluded, as well as near-triploidies/duplication of hypodiploidies 30–39 chromosomes. Pts were stratified into 4 risk groups (VLR/AR1/AR2/VHR) according to DI, Modal Number of Chromosomes (MNC), WBC, CNS/gonadal involvement, presence of VHR features (unfavorable translocations, poor response to prephase, residual disease (MRD) at the end of induction >10-2). VLR was defined as: DI>1.16 or MNC>50, WBC<10×109/L, no CNS/gonadal involvement and no VHR features. Overall Results: Out of 1651 B-lineage pts registered in the 58951 study over a 10-year period (1998-2008), a total of 541 pts had HD>50. Median age was 3 years and median WBC was 5.6×109/L. After prephase, 3% (N=17) were poor responders; initial risk group distribution into VLR/AR1/AR2/VHR was 45%/47%/5%/3%. After induction, 540 (99.8%) reached complete remission, 455 of whom had an MRD evaluation: MRD<10-3 (N=416;91%), MRD <10-2 and >10-3 (N=26;6%) or MRD≥10-2 (N=13;2%). At median follow-up of 6 years, 48 pts (9%) relapsed, 22 pts (4%) died and 6 (1%) died without relapse. The 6-yr EFS was 89% (SE=1.5%). MNC was assessed in 446 pts (82%) with successful karyotypes, MNC ranged from 51 to 66 chromosomes and peaked at 55–56; 87 pts had 51 to 53 chromosomes (HD51-53), 258 pts had 54 to 57 (HD54-57) and 101 pts had ≥58 chromosomes (HD≥58). In these 3 groups, VLR regimen was given to 16%, 50% and 64% respectively. Structural abnormalities were detected in 46% of pts and associated with all MNCs. DI, assessed in 460 pts was <1.16 (N=146), 1.16 to 1.24 (N=240) and ≥1.24 (N=104). There was no strict overlap between the HD≥58 and DI ≥1.24 groups. Prognostic Factors: The only significant prognostic factors for EFS were MNC, DI, TT, DT and MRD. EFS was clearly improved (p<0.001) when the MNC was ≥58 chromosomes: 6-yr EFS was 80% (HD51-53) vs 89% (HD54-57) vs 99% (HD'58). In the last group, all pts had a good response to prephase, only 3 pts had detectable MRD after induction (1pt: MRD>10-2 and 2 pts: MRD≥10-3) and only 1 pt (MNC=58) relapsed. No specific profile of chromosome gains was identified in HD ≥58 since all chromosomes contributed to tri/tetrasomies, except chromosome 1. Likewise, the higher the DI the better the outcome (p=0.01): 6-yr EFS was 83% (DI<1.16) vs 90% (DI≥ 1.16 and <1.24) vs 95% (DI ≥1.24). TT were detected in 168 out of 468 pts, and DT in 242 out of 466 pts. There was no overlap with HD ≥58 since TT and DT were distributed from 52 to 66 chromosomes. One third of TT and of DT had MNC≥58. TT and DT were also of prognostic importance for outcome: the 6-yr EFS rate was 96% (TT) vs 86% (non-TT) (p=0.005) and 94% (DT) vs 84% (non-DT) (p=0.003). A hierarchical variable based on presence of HD≥58, TT or DT showed that HD ≥58 (N=101; 6-yr EFS: 99%) group had a better outcome than TT without HD≥58 (N=115; 6-yr EFS: 93%) and DT without HD≥58 and without +17 (N=55; 6-yr EFS: 84%) groups (p=0.04). We can infer from our results that the good outcome observed for all of the TT and DT was partially due to their association with HD '58. Consequently, the best indicator for excellent outcome was a high MNC (≥58 chromosomes). From our 58951 trial, we can assume that among children with B-ALL and HD>50, those with ≥58 chromosomes, stand every chance of being cured. Our results stress the necessity of karyotype for identifying them since this is the only way to assess MNC. They can also be detected (less accurately) by DI (DI ≥1.24). Therefore, both MNC and DI should be used for stratifying pts in the very low risk groups. Disclosures: No relevant conflicts of interest to declare." @default.
• W2522016529 created "2016-09-30" @default.
• W2522016529 creator A5000382317 @default.
• W2522016529 creator A5003636024 @default.
• W2522016529 creator A5006796499 @default.
• W2522016529 creator A5009969425 @default.
• W2522016529 creator A5011158086 @default.
• W2522016529 creator A5012072301 @default.
• W2522016529 creator A5013848073 @default.
• W2522016529 creator A5015163256 @default.
• W2522016529 creator A5019188950 @default.
• W2522016529 creator A5021012565 @default.
• W2522016529 creator A5021990601 @default.
• W2522016529 creator A5023346779 @default.
• W2522016529 creator A5024388708 @default.
• W2522016529 creator A5027243684 @default.
• W2522016529 creator A5032553284 @default.
• W2522016529 creator A5032769404 @default.
• W2522016529 creator A5033579801 @default.
• W2522016529 creator A5038099791 @default.
• W2522016529 creator A5038875954 @default.
• W2522016529 creator A5048634689 @default.
• W2522016529 creator A5049198404 @default.
• W2522016529 creator A5049976740 @default.
• W2522016529 creator A5057315093 @default.
• W2522016529 creator A5061975824 @default.
• W2522016529 creator A5063170420 @default.
• W2522016529 creator A5067815591 @default.
• W2522016529 creator A5068741704 @default.
• W2522016529 creator A5071405091 @default.
• W2522016529 creator A5078645753 @default.
• W2522016529 creator A5079852624 @default.
• W2522016529 creator A5083143483 @default.
• W2522016529 creator A5085111210 @default.
• W2522016529 date "2011-11-18" @default.
• W2522016529 modified "2023-10-18" @default.
• W2522016529 title "In Childhood B-Lineage Acute Lymphoblastic Leukemia (B-ALL) with Hyperdiploidy >50 Chromosomes, Patients with 58 to 66 Chromosomes Have 99% EFS At 6-Year Follow-up: Results of the EORTC CLG 58951 Trial" @default.
• W2522016529 doi "https://doi.org/10.1182/blood.v118.21.565.565" @default.
• W2522016529 hasPublicationYear "2011" @default.
• W2522016529 type Work @default.
• W2522016529 sameAs 2522016529 @default.
• W2522016529 citedByCount "0" @default.
• W2522016529 crossrefType "journal-article" @default.
• W2522016529 hasAuthorship W2522016529A5000382317 @default.
• W2522016529 hasAuthorship W2522016529A5003636024 @default.
• W2522016529 hasAuthorship W2522016529A5006796499 @default.
• W2522016529 hasAuthorship W2522016529A5009969425 @default.
• W2522016529 hasAuthorship W2522016529A5011158086 @default.
• W2522016529 hasAuthorship W2522016529A5012072301 @default.
• W2522016529 hasAuthorship W2522016529A5013848073 @default.
• W2522016529 hasAuthorship W2522016529A5015163256 @default.
• W2522016529 hasAuthorship W2522016529A5019188950 @default.
• W2522016529 hasAuthorship W2522016529A5021012565 @default.
• W2522016529 hasAuthorship W2522016529A5021990601 @default.
• W2522016529 hasAuthorship W2522016529A5023346779 @default.
• W2522016529 hasAuthorship W2522016529A5024388708 @default.
• W2522016529 hasAuthorship W2522016529A5027243684 @default.
• W2522016529 hasAuthorship W2522016529A5032553284 @default.
• W2522016529 hasAuthorship W2522016529A5032769404 @default.
• W2522016529 hasAuthorship W2522016529A5033579801 @default.
• W2522016529 hasAuthorship W2522016529A5038099791 @default.
• W2522016529 hasAuthorship W2522016529A5038875954 @default.
• W2522016529 hasAuthorship W2522016529A5048634689 @default.
• W2522016529 hasAuthorship W2522016529A5049198404 @default.
• W2522016529 hasAuthorship W2522016529A5049976740 @default.
• W2522016529 hasAuthorship W2522016529A5057315093 @default.
• W2522016529 hasAuthorship W2522016529A5061975824 @default.
• W2522016529 hasAuthorship W2522016529A5063170420 @default.
• W2522016529 hasAuthorship W2522016529A5067815591 @default.
• W2522016529 hasAuthorship W2522016529A5068741704 @default.
• W2522016529 hasAuthorship W2522016529A5071405091 @default.
• W2522016529 hasAuthorship W2522016529A5078645753 @default.
• W2522016529 hasAuthorship W2522016529A5079852624 @default.
• W2522016529 hasAuthorship W2522016529A5083143483 @default.
• W2522016529 hasAuthorship W2522016529A5085111210 @default.
• W2522016529 hasConcept C104317684 @default.
• W2522016529 hasConcept C126322002 @default.
• W2522016529 hasConcept C138626823 @default.
• W2522016529 hasConcept C143998085 @default.
• W2522016529 hasConcept C174475383 @default.
• W2522016529 hasConcept C196166836 @default.
• W2522016529 hasConcept C203014093 @default.
• W2522016529 hasConcept C2776229224 @default.
• W2522016529 hasConcept C2778461978 @default.
• W2522016529 hasConcept C2779823535 @default.
• W2522016529 hasConcept C30481170 @default.
• W2522016529 hasConcept C53226629 @default.
• W2522016529 hasConcept C54355233 @default.
• W2522016529 hasConcept C553184892 @default.
• W2522016529 hasConcept C71924100 @default.
• W2522016529 hasConcept C86803240 @default.
• W2522016529 hasConcept C90924648 @default.
• W2522016529 hasConceptScore W2522016529C104317684 @default.
• W2522016529 hasConceptScore W2522016529C126322002 @default.
• W2522016529 hasConceptScore W2522016529C138626823 @default.
• W2522016529 hasConceptScore W2522016529C143998085 @default.
• W2522016529 hasConceptScore W2522016529C174475383 @default.
• W2522016529 hasConceptScore W2522016529C196166836 @default.
• W2522016529 hasConceptScore W2522016529C203014093 @default.
• W2522016529 hasConceptScore W2522016529C2776229224 @default.

• next